Loading clinical trials...

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders | Clinical Trials | Clareo Health

UNKNOWN

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

NCT05840861•Central South University

Summary

Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability and clinical symptoms in patients with MDD and bipolar disorder(BD) after two months of vortioxetine treatment. The investigators hypothesized that patients with MDD and BP have abnormal mGluR5 availability in certain brain regions, and baseline mGLUR5 availability can predict prognosis the prognosis of MDD and BD. fMRI and NODDI are also used to evaluate the function or neurite condition at baseline and 8 week

Eligibility

Age

18 - 35 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Meet DSM-V criteria for a current depressive episode.
•Being first-episode patients who were medication-naïve;
•Score \>17 on 17-item Hamilton Depression Rating Scale (HDRS), score \>22 on Montgomery-Asberg Depression Rating Scale (MADRS), and score \<6 on Young Mania Rating Scale (YMRS).
•Age 18 to 35.
•Able to give written informed consent.

Exclusion Criteria

•Have a current or past significant medical, neurological or metabolic disorder or head injury
•Have active, significant suicidal ideation or past suicide attempts
•Have implanted metallic devices or any MR contraindications
•Are women who are pregnant or breastfeeding
•Met DSM-5 criteria for substance use disorder
•Met DSM-5 criteria for any current Axis I diagnosis (except Generalized Anxiety Disorder)
•Are MDD patients present with delusions and/or hallucinations

Locations (1)

Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University

Changsha, Hunan, China

Key Dates

Start Date

November 5, 2020

Primary Completion Date

August 21, 2023

Completion Date

September 5, 2023

Last Updated

August 14, 2023

Enrollment

ESTIMATED participants

Conditions

Major Depressive DisorderBipolar Disorder

Interventions

Vortioxetine

DRUG

Quetiapine

DRUG

Contacts

Yan Zhang, MD PhD

CONTACT

13807315182 yan.zhang@csu.edu.cn

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults